Glenmark Pharmaceuticals: Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026
Glenmark Pharmaceuticals (GLENMARK) filed a disclosure titled "Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026". The company is valued at about ₹70,037 crore.
What happened
Glenmark Pharmaceuticals (GLENMARK) filed a disclosure with the exchanges on 5 November 2026 at 05:04 PM titled "Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026".
Company snapshot
Glenmark Pharmaceuticals is a mid-cap company in the Healthcare sector, with a market value of about ₹70,037 crore.
The stock last traded at ₹2,481.8, against a 52-week range of ₹1,801.4–₹2,537.6 (2.2% below the high).
Before this filing the shares had moved +9.1% over the month and +10.9% over three months. Average daily turnover over the last 20 sessions was about ₹140 crore.
Promoters held 46.65% at the end of Q1 FY27. Foreign institutions owned 20.89% and domestic institutions 18.60%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,264 | 46.9 | 1.66 |
| Q2 FY26 | 6,047 | 610.4 | 21.63 |
| Q3 FY26 | 3,901 | 403.2 | 14.29 |
| Q4 FY26 | 3,771 | — | 10.68 |
| Q1 FY27 | 4,018 | 482.9 | 17.11 |
What history shows
This is not the company's first results disclosure: BCEIE has 3 earlier filings of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.0% over five days; 58% of them rose the next day.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- GLENMARK Outlook for the Week
- Glenmark Pharmaceuticals Limited (GLENMARK.BO) Seasonal Returns Chart - Yahoo Finance
- Namita Shah Elevated to Senior Vice President – Global Portfolio at Glenmark Pharmaceuticals
- Glenmark transfers nebulizer brands to subsidiary for ₹223 Cr
- Glenmark Pharmaceuticals elevates Namita Shah to Sr. VP – Global Portfolio
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.